Form 4: Kalaris Therapeutics Director Receives Stock Option Grant

Director Leone D. Patterson was granted 9,000 stock options in Kalaris Therapeutics, Inc. as part of a standard equity incentive.

Summary

• Leone D. Patterson, a Director at Kalaris Therapeutics, Inc. (KLRS), was granted 9,000 stock options on June 3, 2026.
• The options have an exercise price of $4.72 per share.
• The options are scheduled to vest in full on the earlier of June 3, 2027, or the date of the 2027 Annual Meeting of Stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Minor dilution of existing shareholders upon potential future exercise of the options.

Risks

• Market price volatility could impact the future value of the granted options.
• Vesting is subject to continued service, creating a dependency on the director's ongoing tenure.

Future Outlook

The options vest in one year, aligning the director's incentives with the company's performance through June 2027.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board members maintain a vested interest in company performance.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for small-cap biotechnology firms.
• The use of a one-year cliff vesting period is a standard retention mechanism for board members.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on June 3, 2027, or the 2027 Annual Meeting of Stockholders.

Key Dates

Keywords

Kalaris Therapeutics, KLRS, Form 4, Insider Trading, Stock Options, Director Compensation